Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2838)
All Articles published online
|
Oct 7, 2005 (publication date) through Dec 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. Interferon-α plus lamivudine |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i37/5882.htm |
| Number | Citing Articles |
| 1 |
Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt. Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection. Journal of General Internal Medicine 2011; 26(3): 326 doi: 10.1007/s11606-010-1569-5
|
| 2 |
Hans Damerow, Lilly Yuen, Johannes Wiegand, Christine Walker, C.‐Thomas Bock, Stephen Locarnini, Hans L. Tillmann. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. Journal of Medical Virology 2010; 82(11): 1850 doi: 10.1002/jmv.21902
|
| 3 |
Mariana Alves Fonseca, Joanna Zhi Jie Ling, Omar Al‐Siyabi, Vanessa Co‐Tanko, Edwin Chan, Seng Gee Lim. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta‐analysis. Journal of Viral Hepatitis 2020; 27(7): 650 doi: 10.1111/jvh.13283
|
| 4 |
G.A. Niro, R. Fontana, D. Gioffreda, S. Fiorella, L. Accadia, A. Iacobellis, N. Caruso, P. Conoscitore, A. Andriulli. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: A pilot study. Digestive and Liver Disease 2007; 39(9): 857 doi: 10.1016/j.dld.2007.06.002
|
| 5 |
Ri‐Cheng Mao, You‐Kuan Yin, Yan‐Li Qin, Xiang‐Hui Wu, Xin‐Hua Weng, Ji‐Ming Zhang, Mengji Lu. Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy. Hepatology Research 2009; 39(1): 14 doi: 10.1111/j.1872-034X.2008.00411.x
|
| 6 |
Hyun Woong Lee, Joung Il Lee, Soon Ho Um, Sang Hoon Ahn, Hye Young Chang, Yong Kwang Park, Sun Pyo Hong, Young Myoung Moon, Kwang‐Hyub Han. Combination therapy of thymosin alpha‐1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. Journal of Gastroenterology and Hepatology 2008; 23(5): 729 doi: 10.1111/j.1440-1746.2008.05387.x
|
| 7 |
Masahito Minami, Takayuki Katayama, Rei Sendo, Takeshi Okanoue, Toshikazu Yoshikawa. Interferon and nucleoside analog combination therapy for hepatitis B. Clinical Journal of Gastroenterology 2010; 3(2): 69 doi: 10.1007/s12328-010-0135-3
|
| 8 |
Kwan Sik Lee, Dong Joon Kim. Management of Chronic Hepatitis B. The Korean Journal of Hepatology 2007; 13(4): 447 doi: 10.3350/kjhep.2007.13.4.447
|
| 9 |
P. D. Griffiths. Mixed results from combination therapy. Reviews in Medical Virology 2011; 21(6): 333 doi: 10.1002/rmv.719
|
| 10 |
Nripen Saikia, Rupjyoti Talukdar, Subhasish Mazumder, Sudeep Khanna, Rakesh Tandon. Management of patients with HBeAg-negative chronic hepatitis B. Postgraduate Medical Journal 2007; 83(975): 32 doi: 10.1136/pgmj.2006.044826
|
| 11 |
M. KUMAR, S. K. SARIN. Systematic review: combination therapies for treatment‐naïve chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2008; 27(12): 1187 doi: 10.1111/j.1365-2036.2008.03695.x
|
| 12 |
Vito Di Marco, Antonio Craxì. Chronic hepatitis B: who to treat and which choice of treatment?. Expert Review of Anti-infective Therapy 2009; 7(3): 281 doi: 10.1586/eri.09.4
|
| 13 |
Ketan Kulkarni, Ira M. Jacobson, Bud C. Tennant. The Role of the Woodchuck Model in the Treatment of Hepatitis B Virus Infection. Clinics in Liver Disease 2007; 11(4): 707 doi: 10.1016/j.cld.2007.08.012
|
| 14 |
Konstantinos Tziomalos. Combination treatment in HBeAg-negative chronic hepatitis B. World Journal of Hepatology 2009; 1(1): 43-47 doi: 10.4254/wjh.v1.i1.43
|
| 15 |
Rui Huang, Yingying Hao, Jun Zhang, Chao Wu. Interferon‐alpha plus adefovir combination therapy versus interferon‐alpha monotherapy for chronic hepatitis B treatment: A meta‐analysis. Hepatology Research 2013; 43(10): 1040 doi: 10.1111/hepr.12058
|
| 16 |
|
| 17 |
Manoj Kumar, Shiv K Sarin. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2008; 2(4): 465 doi: 10.1586/17474124.2.4.465
|
| 18 |
Erica Villa, Barbara Lei, Gloria Taliani, Amalia Graziosi, Rosina Critelli, Monica Luongo, William Gennari, Marcello Bianchini, Ilva Ferretti. Pretreatment with Pegylated Interferon Prevents Emergence of Lamivudine Mutants in Lamivudine-Naive Patients: A Pilot Study. Antiviral Therapy 2009; 14(8): 1081 doi: 10.3851/IMP1465
|
| 19 |
Astrid Wiens, Luana Lenzi, Rafael Venson, Maria Lúcia Alves Pedroso, Cassyano Januário Correr, Roberto Pontarolo. Economic evaluation of treatments for chronic hepatitis B. The Brazilian Journal of Infectious Diseases 2013; 17(4): 418 doi: 10.1016/j.bjid.2012.12.005
|